跳至主要内容
临床试验/JPRN-jRCTs041180139
JPRN-jRCTs041180139已完成2 期

Feasibility study of dose dense chemotherapy for primary breast cancer patients - Feasibility study of dd-chemotherapy for primary breast cancer patients

Saito Kanako0 个研究点目标入组 30 人开始时间: 2019年3月29日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
30

研究概览

简要总结

Thirty breast cancer patients were treated with dose-dense chemotherapy. The completion rate was 76%. The completion rate was 88% in 26 patients, excluding 3 patient requests and 1 ineligible patient among the discontinued cases. The 3 discontinuations were due to liver dysfunction in 2 cases and pneumonia in 1 case; no cases of PCP pneumonia were observed. After the completion of enrollment, doxorubicin and paclitaxel were revised in the package inserts, and this treatment is now covered by insurance.

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 <= 75age old(—)
性别
Female

入选标准

  • 1. Invasive ductal carcinoma
  • 2. Stage I-III
  • 3. Age >=20 and 75=<
  • 4. ECOG PS 0 or 1
  • 5. Vital organ functions are preserved
  • 6. Written IC

排除标准

  • 1. Active multiple primary cancer (synchronous multiple primary cancer and invasive cancer of other organs)
  • 2. History of drug-related allergy which could hinder planned treatment
  • 3. Any history or complication of following cardiac disorders
  • - History of congestive heart failure, cardiac infarction
  • - Complication requires treatment such as: ischemic cardiac disorder, arrhythmia, valvular heart disease
  • 4. Poorly controlled hypertension
  • 5. Poorly controlled diabetes
  • 6. Pregnancy
  • 7. Ineligible to the trial based on decision of an investigator

研究者

发起方
Saito Kanako

相似试验